Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Receivables (2023 - 2025)

Historic Receivables for Zhengye Biotechnology Holding (ZYBT) over the last 3 years, with Q2 2025 value amounting to $5.2 million.

  • Zhengye Biotechnology Holding's Receivables changed N/A to $5.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $10.6 million for FY2024, which is 2056.92% down from last year.
  • As of Q2 2025, Zhengye Biotechnology Holding's Receivables stood at $5.2 million.
  • In the past 5 years, Zhengye Biotechnology Holding's Receivables registered a high of $13.1 million during Q4 2023, and its lowest value of $5.2 million during Q2 2025.
  • Its 3-year average for Receivables is $8.9 million, with a median of $8.4 million in 2024.
  • The largest annual percentage gain for Zhengye Biotechnology Holding's Receivables in the last 5 years was 3575.58% (2024), contrasted with its biggest fall of 3575.58% (2024).
  • Zhengye Biotechnology Holding's Receivables (Quarter) stood at $13.1 million in 2023, then plummeted by 35.76% to $8.4 million in 2024, then tumbled by 37.95% to $5.2 million in 2025.
  • Its Receivables stands at $5.2 million for Q2 2025, versus $8.4 million for Q4 2024 and $13.1 million for Q4 2023.